Moonlight Therapeutics Launches First-in-Human Phase I Trial of MOON101 for Peanut Allergy Moonlight Therapeutics, Inc., a clinical-stage biotechnology company focused on developing innovative treatments for food allergies, has announced the…
Alliance Clinical Network and Atlas Clinical Research Complete Merger to Create Expanded National Clinical Research Platform Alliance Clinical Network and Atlas Clinical Research have announced the successful completion of a…
Camizestrant Combination Reduced Risk of First and Second Disease Progression in ESR1-Mutant Advanced HR-Positive Breast Cancer in SERENA-6 AstraZeneca has announced updated positive findings from its pivotal Phase III SERENA-6…
Iza-Bren Significantly Improves Overall and Progression-Free Survival in Triple-Negative Breast Cancer and Esophageal Cancer SystImmune, Inc., a clinical-stage biotechnology company focused on developing innovative cancer therapies, and Bristol Myers Squibb…
Hims & Hers Completes Acquisition of Eucalyptus, Strengthening Clinically Supported Weight Management Services in Germany Hims & Hers Health, Inc. has officially completed its acquisition of Eucalyptus, the parent company…
Incyte Reports Positive Phase 3 frontMIND Results for Tafasitamab Plus Lenalidomide Added to R-CHOP in First-Line DLBCL and HGBL Incyte Corporation (Nasdaq: INCY) has announced positive results from the pivotal…
C2N Diagnostics and SouthGenetics Partner to Expand Access to Alzheimer’s Blood Biomarker Testing Across Latin America and the Caribbean C2N Diagnostics, LLC, a specialty diagnostics company focused on advancing blood-based…
Corsair Pharma Reports Successful Phase 1 Results for TRX-248 Transdermal System in Pulmonary Arterial Hypertension Corsair Pharma, Inc., a private biopharmaceutical company focused on innovative drug delivery technologies, has announced…
Integrated DNA Technologies Introduces End-to-End Oncology Research Workflows Optimized with Illumina, Inc. Software for Faster Insights Integrated DNA Technologies (IDT), a Danaher company and a global leader in genomics solutions,…
Shionogi’s XOCOVA® Becomes First FDA-Approved Oral Treatment for Preventing COVID-19 Following Exposure Shionogi & Co., Ltd. has announced a significant regulatory milestone for its antiviral medicine XOCOVA® (ensitrelvir), with the…
Avenzo Reports Updated Phase 1 Data for AVZO-021 Showing Clinical Activity and Favorable Tolerability in Heavily Pretreated HR+/HER2- Breast Cancer Avenzo Therapeutics has announced updated clinical findings from the Phase…
Rallybio and Avenzo Therapeutics Announce Merger Backed by $215 Million Financing to Advance Next-Generation Oncology Pipeline Rallybio Corporation and Avenzo Therapeutics have entered into a definitive merger agreement that will…